Remove 2022 Remove Doctors Remove Safety Remove Side effects
article thumbnail

EMA approves biosimilar interchangeability in EU

European Pharmaceutical Review

This interchangeability refers to the fact that a reference medicine can be substituted by a biosimilar, without risk, side effects or outcomes different to the original drug. Clinically, it is common practice for doctors to rotate patients between different biologics. New regulatory guidance could lead to UK biosimilar boom.

article thumbnail

FDA backs pharmacist prescribing of Paxlovid for COVID

pharmaphorum

If those criteria cannot be met, the pharmacist will have to refer the patient to a doctor, advanced practice registered nurse, or physician assistant able to prescribed the drug. Now, in addition to doctors and providers, the FDA announced pharmacists with your medical information can prescribe Paxlovid to patients.

FDA 109
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Healthcare Watch October 2023

PM360

Doctor Docs: Targeting Trust Between Pharma and HCPs A new study shows the crucial link in pharma marketers’ digital engagement strategy with HCPs is in jeopardy—trust. doctors are calling two particular drugs “paradigm-shifting”—tirzepatide, sold as Mounjaro , and semaglutide, sold as the brands Ozempic , Wegovy , and Rybelsus.

article thumbnail

How Real-World Data Can Contribute to Improved Mental Health Treatment

PM360

above pre-pandemic levels by Q2 2022. This is different from clinical trials which are really designed to look at efficacy and safety in a very controlled environment, so controlled trials are very good at answering those two questions. They’re wonderful medications, blockbuster sales, but real side effects.

article thumbnail

Tackling immune-mediated disease with CAR Tregs

European Pharmaceutical Review

These are all diseases that are highly prevalent in the population and are generally treated with drugs that are broadly immunosuppressive; while some of these drugs are beneficial and do ameliorate some symptoms, these patients experience side effects including increased susceptibility to infections. Supporting evidence.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

Doctors, caregivers, life sciences companies, and even companies in other industries have attempted to answer this question for as long as medications have been available. Care providers can view adherence data, patient-reported side effects, and connect directly to their patients if needed. But it is not a simple answer.

article thumbnail

How to Work with Patient Advocates, Influencers, and Ambassadors

PM360

Then, the MRL team and the influencer must align on where there is flexibility within messaging while still abiding to brand safety guidelines, as you don’t want to lose the authenticity that the influencer brings. Typically, we think of patient partnerships in terms of their external impact—for example, to help educate doctors and payers.